Press Releases

Date Title and Summary
Toggle Summary Kezar Life Sciences to Present at The BMO Prescriptions for Success Healthcare Conference
SOUTH SAN FRANCISCO, Calif., Dec. 05, 2018 (GLOBE NEWSWIRE) -- Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing novel small molecule therapeutics to treat unmet needs in autoimmunity and cancer, today announced that John Fowler, Chief
Toggle Summary Kezar Life Sciences Reports Third Quarter 2018 Financial Results and Provides Business Update
SOUTH SAN FRANCISCO, Calif. , Nov. 08, 2018 (GLOBE NEWSWIRE) -- Kezar Life Sciences, Inc. (Nasdaq: KZR ), a clinical-stage biotechnology company discovering and developing novel small molecule therapeutics to treat unmet needs in autoimmunity and cancer, today announced its third quarter 2018
Toggle Summary Kezar Life Sciences to Present at Jefferies 2018 London Healthcare Conference
SOUTH SAN FRANCISCO, Calif. , Nov. 07, 2018 (GLOBE NEWSWIRE) -- Kezar Life Sciences , Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing novel small molecule therapeutics to treat unmet needs in autoimmunity and cancer, today announced that John Fowler , Chief
Toggle Summary Kezar Life Sciences to Present at 2018 Wells Fargo Healthcare Conference
SOUTH SAN FRANCISCO, Calif., Aug. 29, 2018 (GLOBE NEWSWIRE) -- Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing novel small molecule therapeutics to treat unmet needs in autoimmunity and cancer, today announced that John Fowler, Chief
Toggle Summary Kezar Life Sciences Reports Second Quarter 2018 Financial Results and Provides Business Update
SOUTH SAN FRANCISCO, Calif. , Aug. 09, 2018 (GLOBE NEWSWIRE) -- Kezar Life Sciences, Inc. (Nasdaq: KZR ), a clinical-stage biotechnology company discovering and developing novel small molecule therapeutics to treat unmet needs in autoimmunity and cancer, today announced its second quarter 2018
Toggle Summary Kezar Life Sciences Announces Closing of Initial Public Offering and Exercise in Full of the Underwriters' Option to Purchase Additional Shares
SOUTH SAN FRANCISCO, Calif. , June 25, 2018 /PRNewswire/ --  Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing novel small molecule therapeutics to treat unmet needs in autoimmunity and cancer, announced today the closing of its initial
Toggle Summary Kezar Life Sciences Announces Pricing of Initial Public Offering
SOUTH SAN FRANCISCO, Calif. , June 20, 2018 /PRNewswire/ --  Kezar Life Sciences, Inc. ( Nasdaq:KZR ), a clinical-stage biotechnology company discovering and developing novel small molecule therapeutics to treat unmet needs in autoimmunity and cancer, announced today that it has priced its initial
Toggle Summary Kezar Life Sciences Strengthens Management Team
SOUTH SAN FRANCISCO, Calif., May 1, 2018 /PRNewswire/ -- Kezar Life Sciences, a private, clinical-stage biotechnology company discovering and developing novel small molecule therapeutics, today announced the appointments of Niti Goel, MD, as Chief Medical Officer and Marc Belsky as Chief Financial
Toggle Summary Kezar Life Sciences to Present at 36th Annual J.P. Morgan Healthcare Conference
SOUTH SAN FRANCISCO, Calif., Jan. 3, 2018 /PRNewswire/ -- Kezar Life Sciences, a private, clinical-stage biopharmaceutical company developing novel small molecule therapeutics, today announced that John Fowler, Chief Executive Officer, will present at the 36th Annual J.P.
Toggle Summary Kezar Life Sciences to Present Multiple Abstracts at the 2017 American College of Rheumatology Annual Meeting in San Diego
Kezar Scientific Leaders to discuss Phase 1a data with KZR-616, animal model results, and new insights into immunoproteasome biology during the ACR 2017 Annual Meeting SOUTH SAN FRANCISCO, Oct. 31, 2017 /PRNewswire/ --Kezar Life Sciences, a private, clinical-stage biopharmaceutical company